NCT05375084
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05375084
Title SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Navire Pharma Inc., a BridgeBio company
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Highlands Oncology Springdale Arkansas 72762 United States Details
Scripps Clinic Torrey Pines La Jolla California 92037 United States Details
Providence Medical Foundation Santa Rosa California 95403 United States Details
Memorial Regional Hospital (Memorial Cancer Institute) Hollywood Florida 33021 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland 21224 United States Details
Henry Ford Hospital Detroit Michigan 48202 United States Details
Roswell Park Cancer Institute Buffalo New York 14203 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
Providence Portland Medical Center Portland Oregon 97213 United States Details
University of Pennsylvania (Abramson Cancer Center) Philadelphia Pennsylvania 19104 United States Details
Medical University of South Carolina (MUSC) - Hollings Cancer Center Charleston South Carolina 29425 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Millennium Research and Clinical Development Houston Texas 77090 United States Details
NEXT Oncology Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field